OBJECTIVE: Cardia, non-cardia and intestinal and diffuse subtypes of gastric cancer may have different trends and etiological factors. However, the available information is not always collected in population cancer registries, and heterogeneous criteria have been applied for the histopathological classification of tumors. We describe the pathological features of incident gastric and esophageal cancers identified within the European Prospective Investigation into Cancer and Nutrition (EPIC). MATERIAL AND METHODS: In an investigation on gastric and esophageal cancer (EUR-GAST) in the EPIC project, a validation study of diagnoses reported by EPIC centers was conducted by a European panel of pathologists. Original pathology reports, stained slides of tumors and the respective paraffin blocks were requested from the centers. RESULTS: The whole series encompassed 467 cancer cases (gastric and esophageal cancers). Material was available for histopathological validation in 263 cases (56%); in the remaining cases, information was retrieved from the original reports (n=110; 24%) or codes provided by the EPIC centers (n=94; 20%). Among cases submitted to histopathological validation reported originally as unknown histotype or unknown site, a specific diagnosis was made in 95% and 74% of the cases, respectively. In cases for which only the original reports were available, the respective percentages were 46% and 67%. Gastric adenocarcinomas were classified according to site (cardia (29.4%), non-cardia (48.2%) and unknown (22.4%)) and histological type (intestinal (33.4%), diffuse (33.7%) and mixed, unclassified or unknown (32.9%)). Frequency of cardia was higher in Northern countries (35%) than in Mediterranean countries (18%). CONCLUSIONS: In addition to providing epidemiological data within the EPIC cohort on gastric and esophageal adenocarcinomas, the results reported here confirm the relevance of a validation study, notably for multicenter studies.
OBJECTIVE: Cardia, non-cardia and intestinal and diffuse subtypes of gastric cancer may have different trends and etiological factors. However, the available information is not always collected in population cancer registries, and heterogeneous criteria have been applied for the histopathological classification of tumors. We describe the pathological features of incident gastric and esophageal cancers identified within the European Prospective Investigation into Cancer and Nutrition (EPIC). MATERIAL AND METHODS: In an investigation on gastric and esophageal cancer (EUR-GAST) in the EPIC project, a validation study of diagnoses reported by EPIC centers was conducted by a European panel of pathologists. Original pathology reports, stained slides of tumors and the respective paraffin blocks were requested from the centers. RESULTS: The whole series encompassed 467 cancer cases (gastric and esophageal cancers). Material was available for histopathological validation in 263 cases (56%); in the remaining cases, information was retrieved from the original reports (n=110; 24%) or codes provided by the EPIC centers (n=94; 20%). Among cases submitted to histopathological validation reported originally as unknown histotype or unknown site, a specific diagnosis was made in 95% and 74% of the cases, respectively. In cases for which only the original reports were available, the respective percentages were 46% and 67%. Gastric adenocarcinomas were classified according to site (cardia (29.4%), non-cardia (48.2%) and unknown (22.4%)) and histological type (intestinal (33.4%), diffuse (33.7%) and mixed, unclassified or unknown (32.9%)). Frequency of cardia was higher in Northern countries (35%) than in Mediterranean countries (18%). CONCLUSIONS: In addition to providing epidemiological data within the EPIC cohort on gastric and esophageal adenocarcinomas, the results reported here confirm the relevance of a validation study, notably for multicenter studies.
Authors: Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni Journal: Gastric Cancer Date: 2016-12-30 Impact factor: 7.370
Authors: Annika Steffen; José-Maria Huerta; Elisabete Weiderpass; H B As Bueno-de-Mesquita; Anne M May; Peter D Siersema; Rudolf Kaaks; Jasmine Neamat-Allah; Valeria Pala; Salvatore Panico; Calogero Saieva; Rosario Tumino; Alessio Naccarati; Miren Dorronsoro; Emilio Sánchez-Cantalejo; Eva Ardanaz; J Ramón Quirós; Bodil Ohlsson; Mattias Johansson; Bengt Wallner; Kim Overvad; Jytte Halkjaer; Anne Tjønneland; Guy Fagherazzi; Antoine Racine; Françoise Clavel-Chapelon; Tim J Key; Kay-Tee Khaw; Nick Wareham; Pagona Lagiou; Christina Bamia; Antonia Trichopoulou; Pietro Ferrari; Heinz Freisling; Yunxia Lu; Elio Riboli; Amanda J Cross; Carlos A Gonzalez; Heiner Boeing Journal: Int J Cancer Date: 2015-02-09 Impact factor: 7.396
Authors: Harindra Jayasekara; Robert J MacInnis; Leila Lujan-Barroso; Ana-Lucia Mayen-Chacon; Amanda J Cross; Bengt Wallner; Domenico Palli; Fulvio Ricceri; Valeria Pala; Salvatore Panico; Rosario Tumino; Tilman Kühn; Rudolf Kaaks; Kostas Tsilidis; Maria-Jose Sánchez; Pilar Amiano; Eva Ardanaz; María Dolores Chirlaque López; Susana Merino; Joseph A Rothwell; Marie-Christine Boutron-Ruault; Gianluca Severi; Hanna Sternby; Emily Sonestedt; Bas Bueno-de-Mesquita; Heiner Boeing; Ruth Travis; Torkjel M Sandanger; Antonia Trichopoulou; Anna Karakatsani; Eleni Peppa; Anne Tjønneland; Yi Yang; Allison M Hodge; Hazel Mitchell; Andrew Haydon; Robin Room; John L Hopper; Elisabete Weiderpass; Marc J Gunter; Elio Riboli; Graham G Giles; Roger L Milne; Antonio Agudo; Dallas R English; Pietro Ferrari Journal: Int J Cancer Date: 2021-02-22 Impact factor: 7.316
Authors: Antonio Agudo; Catalina Bonet; Núria Sala; Xavier Muñoz; Núria Aranda; Ana Fonseca-Nunes; Françoise Clavel-Chapelon; Marie Christine Boutron-Ruault; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Sara Grioni; J Ramón Quirós; Esther Molina; Carmen Navarro; Aurelio Barricarte; Saioa Chamosa; Naomi E Allen; Kay-Tee Khaw; H Bas Bueno-de-Mesquita; Peter D Siersema; Mattijs E Numans; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Rudof Kaaks; Federico Canzian; Heiner Boeing; Karina Meidtner; Mattias Johansson; Malin Sund; Jonas Manjer; Kim Overvad; Anne Tjonneland; Eiliv Lund; Elisabete Weiderpass; Mazda Jenab; Veronika Fedirko; G Johan A Offerhaus; Elio Riboli; Carlos A González; Paula Jakszyn Journal: Carcinogenesis Date: 2013-02-06 Impact factor: 4.944